There are at least three splicing variants for hDMTF1 alpha, beta and gamma.

20 Exons.

Major transcript: 3.9kb (human) (and 3.75kb in the mouse).

In mus musculus, the pseudogene of Dmtf1 exists on chromosome XE3.
NT 039716, gi:149272292.

The human DMTF1alpha protein consists of 760 amino acids; DMTF1beta, 272 amino acids; and DMTF1gamma, 285 amino acids. Mouse Dmp1 consists of 761 amino acids.

Dmtf1 is a MYB-like transcription factor isolated in a yeast two-hybrid screen of a mouse T lymphocyte library with cyclin D2 bait. It binds to a consensus sequence CCCG(G/T)ATG(T/C) that is also recognized by Ets family proteins. DMTF1 is a novel tumor suppressor that receives signals from oncogenic RAS and activates the ARF - P53 pathway. D-type cyclins antagonize the activity of Dmtf1 when E2F sites are not on the promoter; however, they synergize with Dmtf1 on the Arf promoter. Recent study shows significant involvement of DMTF1 in human non-small-cell lung carcinomas.

Mouse Dmtf1 protein is expressed in the testis, thymus, spleen, brain, lung, and kidney.

Both human and mouse DMTF1 alpha proteins are localized in the nucleus.

Dmtf1-null mice are prone to spontaneous tumor development, which was accelerated when the animals were neonatally treated with ionizing radiation or dimethylbenzanthracene. Lung adenomas/adenocarcinomas were the most common tumors found in Dmtf1-deficient mice. Eµ-Myc-induced lymphomagenesis was significantly accelerated in Dmtf1-deficient mice. The retention and expression of the wild-type Dmtf1 allele in tumors arising in heterozygotes indicated that Dmtf1 is haplo-insufficient for tumor suppression. The low frequency of Arf deletion and p53 mutation in tumors from Dmtf1-knockout mice suggested that Dmtf1 is a physiological regulator of the Arf-p53 pathway in vivo.
The DMTF1 promoter is activated by the oncogenic RAS - RAF - MEK - ERK - JUN pathway, and the induction of ARF by RAS is DMTF1-dependent. Thus, DMTF1 is a critical mediator of p19ARF in response to oncogenic RAS signaling. The importance of dmp1 in P53 regulation was recently demonstrated by crossing Dmtf1-deficient mice with K-ras^LA transgenic mice. The Dmtf1 promoter is repressed by overexpression of E2Fs and also by physiological mitogenic signaling. Thus, DMTF1 is a marker of cells that have exited from the cell cycle. The DMTF1 promoter is repressed by genotoxic stimuli mediated by NF-kappa B, and repression of the ARF promoter by genotoxic stimuli is DMP1-dependent. Very little studies have been conducted on the post-translational modifications for DMTF1.

Human DMTF1 vs. mouse Dmtf1: 95% (723/761), positives 97% (739/761) at the amino acids level.
Mouse Dmtf1 vs. mouse TTF-1 (transcription termination factor 1): Identities 29% (90/309), positives 47% (148/309).
Mouse Dmtf1 vs. mouse C-myb: Identities 32% (23/71), positives 54% (39/71).
Mouse Dmtf1 vs. mouse A-myb: Identities 29% (31/106), positives 50% (54/106).
Mouse Dmtf1 vs. mouse B-myb: Identities 27% (22/80), positives 53% (43/80)

Point mutations for human DMTF1 in human cancer or other human disorders have not been reported.
Promoter hypermethylation for the hDMTF1 promoter is very rare ( around 2%) in human non-small-cell lung carcinomas.
Single nucleotide polymorphisms for hDMTF1 are shown in http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=9988.

N/A.

N/A.